Acta Scientific Pharmaceutical Sciences (ISSN: 2581-883X)

Perspective Volume 4 Issue 6

Nitrosamine Impurities in Pharmaceutical Drugs

Tabrez Shaikh*

Lab Manager at Indoco Research Centre, Navimumbai, Maharashtra, India

*Corresponding Author: Tabrez Shaikh, Lab Manager at Indoco Research Centre, Navimumbai, Maharashtra, India.

Received: January 28, 2020; Published: June 01, 2020


FDA and EMA in mid of June 2018 became aware of the presence of Nitrosamine impurity in generic drug substances and drug product, valsartan an angiotensin II receptor blockers (ARBs) or ‘Sartans’ class medicines which is used to treat patients with hypertension (high blood pressure) and heart. Later, various Nitrosamine impurities were detected in other sartan and non-sartan drug substances and drug products. This announcement leads to voluntarily recall hundreds of batches of these generic versions by pharmaceutical distributor worldwide.





Citation: Tabrez Shaikh. “Nitrosamine Impurities in Pharmaceutical Drugs".Acta Scientific Pharmaceutical Sciences 4.6 (2020): 27.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US